Patents Represented by Attorney, Agent or Law Firm Elliot M. Olstein
-
Patent number: 8318179Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunization comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.Type: GrantFiled: June 3, 2005Date of Patent: November 27, 2012Assignee: ISIS Innovation, Ltd.Inventors: Martin Maiden, Ian Feavers, Andrew Pollard
-
Patent number: 8252578Abstract: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided.Type: GrantFiled: January 24, 2011Date of Patent: August 28, 2012Assignee: Xenon Pharmaceuticals Inc.Inventors: Yigal P Goldberg, Rajender K Kamboj
-
Patent number: 8105480Abstract: A process for treating a heavy oil which comprises subjecting a heavy oil to cavitation to reduce the viscosity of the heavy oil. The treated heavy oil, which has a reduced viscosity and specific gravity, thus is more pumpable and transportable, which facilitates further processing. The treated heavy oil also can be fractionated with less severity than untreated heavy oil.Type: GrantFiled: November 13, 2007Date of Patent: January 31, 2012Assignee: Fractal Systems, Inc.Inventors: Michel Chornet, Esteban Chornet
-
Patent number: 8080693Abstract: A process for converting methanol to ethanol which comprises reacting methanol and carbon monoxide in the presence of a catalyst to produce a product comprising at least 25 mole % methyl acetate and, in some instances, acetic acid. The acetic acid then is reacted with at least one alcohol to produce at least one acetate selected from methyl acetate, ethyl acetate, and butyl acetate. The at least one acetate (if produced) and the methyl acetate produced as a result of reacting methanol and carbon monoxide then are hydrogenated to produce ethanol. Syngas may be produced from biomass to produce all or a portion of the methanol, hydrogen, and carbon monoxide requirements for the process.Type: GrantFiled: February 20, 2009Date of Patent: December 20, 2011Assignee: Enerkem, Inc.Inventors: Esteban Chornet, Boris Valsecchi, Yasmin Avila, Betty Nguyen, Jean-Michel Lavoie
-
Patent number: 8067219Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).Type: GrantFiled: September 14, 2010Date of Patent: November 29, 2011Assignees: Xenon Pharmaceuticals Inc., University of British ColumbiaInventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
-
Patent number: 7951528Abstract: The invention is directed to a method for detecting colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of transthyretin in said isolated sample material, and c) comparing the determined level of transthyretin with a reference value. The invention is further directed to a method for discriminating between colorectal adenoma and colorectal carcinoma as well as to a method for monitoring the course of colorectal adenoma and/or colorectal carcinoma and/or the treatment of colorectal adenoma and/or colorectal carcinoma. Moreover, the invention is directed to a test system and an array for use in these methods. Furthermore, the invention is directed to the use of transthyretin as a biomarker for a detection of colorectal adenoma and/or colorectal carcinoma in an individual.Type: GrantFiled: August 13, 2004Date of Patent: May 31, 2011Assignee: Invidumed GmbHInventors: Hartmut Juhl, Kerstin David
-
Patent number: 7947272Abstract: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.Type: GrantFiled: July 13, 2006Date of Patent: May 24, 2011Assignees: Tolerx, Inc., Isis Innovation, Ltd., Cambridge University Technical Services, Ltd.Inventors: Mark Frewin, Herman Waldmann, Scott Gorman, Geoff Hale, Patricia Rao, Tadeusz Kornaga, Douglas Ringler, Stephen Cobbold, Dawn Winsor-Hines
-
Patent number: 7943035Abstract: A treated oil, such as a treated heavy oil, which has a viscosity which is lower than the viscosity of the oil prior to the treatment thereof (i.e., the initial oil). The temperature at which 80 mass % of the treated oil has boiled is within 25° C. of temperature at which 80 mass % of the oil prior to the treatment thereof has boiled. Thus, the treated oil and the oil prior to the treatment thereof, have distillation curves or boiling point curves which are the same as or approximate to each other.Type: GrantFiled: December 6, 2007Date of Patent: May 17, 2011Assignee: Fractal Systems, Inc.Inventors: Michel Chornet, Esteban Chornet
-
Patent number: 7893206Abstract: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e., capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g., by recombinant means. Methods for identifying modulators of HFE2A are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering a therapeutically effective amount of an HFE2A modulator are provided.Type: GrantFiled: February 9, 2009Date of Patent: February 22, 2011Assignee: Xenon Pharmaceuticals Inc.Inventors: Yigal P. Goldberg, Rajender K. Kamboj
-
Patent number: 7883842Abstract: The present invention is directed to a method for detecting colorectal adenoma and/or colorectal carcinoma comprising the steps: a) providing an isolated sample material which has been taken from an individual, b) determining the level of C3a or a derivative thereof in said isolated sample material, c) comparing the determined level of C3a or a derivative thereof with one or more reference values. The invention is further directed to a method for discriminating between colorectal adenoma and colorectal carcinoma as well as to a method for monitoring the course of colorectal adenoma and/or colorectal carcinoma and/or the treatment of colorectal adenoma and/or colorectal carcinoma. Moreover, the invention is directed to a test system and an array for use in these methods. Furthermore, the invention is directed to the use of C3a as a biomarker for a detection of colorectal adenoma and/or colorectal carcinoma in an individual.Type: GrantFiled: August 11, 2005Date of Patent: February 8, 2011Assignee: Invidumed GmbHInventors: Hartmut Juhl, Kerstin David, Anne-Kristin Fentz
-
Patent number: 7816075Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.Type: GrantFiled: July 11, 2005Date of Patent: October 19, 2010Assignees: Xenon Pharmaceuticals Inc., Wisconsin Alumni Research FoundationInventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
-
Patent number: 7785886Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).Type: GrantFiled: April 28, 2004Date of Patent: August 31, 2010Assignees: Xenon Pharmaceuticals, Inc., Univ. of British ColumbiaInventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
-
Patent number: 7732428Abstract: A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.Type: GrantFiled: May 13, 1999Date of Patent: June 8, 2010Assignee: Innovata LimitedInventor: Colin Brown
-
Patent number: 7696151Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.Type: GrantFiled: July 11, 2005Date of Patent: April 13, 2010Assignees: Xenon Pharmaceuticals Inc., Wisconsin Alumni Research FoundationInventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
-
Patent number: 7659082Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.Type: GrantFiled: February 19, 2003Date of Patent: February 9, 2010Assignee: Xenon Pharmaceuticals Inc.Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
-
Patent number: 7635398Abstract: A method of purifying a biodiesel fuel by contacting the biodiesel fuel with at least one adsorbent material, such as magnesium silicate. Such method removes impurities, such as soap, formed during the production of biodiesel fuels.Type: GrantFiled: October 1, 2004Date of Patent: December 22, 2009Assignee: The Dallas Group of America, Inc.Inventors: Bryan Bertram, Christopher Abrams, Brian S. Cooke
-
Patent number: 7592006Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.Type: GrantFiled: April 7, 1998Date of Patent: September 22, 2009Assignee: Université Catholique de LouvainInventors: Herve Bazin, Dominique Latinne
-
Patent number: 7560036Abstract: The invention relates to a method of fabricating a microneedle array in a substrate, a drug delivery device comprising one or more microneedles extending upwards from the front surface of the substrate, the microneedles having a generally conical-shaped body defined by a plurality of surfaces sloping upwards from a relatively broad base to a tip, and one or more substances coating the microneedles, the one or more substances being operable to be administered to a patient, wherein the tips of the one or more microneedles are sufficiently sharp to penetrate an outer layer of the skin of the patient, and a method of administering one or more substances to a patient using the device.Type: GrantFiled: May 20, 2005Date of Patent: July 14, 2009Assignee: Apogee Technology, Inc.Inventors: Nevenka Golubovic-Liakopoulos, Glenn Fricano, Michael Danielson
-
Patent number: 7511018Abstract: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e., capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g., by recombinant means. Methods for identifying modulators of HFE2A are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering a therapeutically effective amount of an HFE2A modulator are provided.Type: GrantFiled: August 4, 2005Date of Patent: March 31, 2009Assignee: Xenon Pharmaceuticals, Inc.Inventors: Yigal P. Goldberg, Rajender K. Kamboj
-
Patent number: 7465790Abstract: A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target.Type: GrantFiled: October 9, 2001Date of Patent: December 16, 2008Assignee: ISIS INNOVATION, Inc.Inventors: Herman Waldmann, Mark Raymond Frewin, Lisa Kim Gilliland, Luis Richardo Simoes da Silva Graca